ClinicalTrials.gov record
Completed Phase 1 Interventional

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

ClinicalTrials.gov ID: NCT02892123

Public ClinicalTrials.gov record NCT02892123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Study identification

NCT ID
NCT02892123
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Jazz Pharmaceuticals
Industry
Enrollment
279 participants

Conditions and interventions

Interventions

  • Capecitabine Drug
  • Paclitaxel Drug
  • Tucatinib Drug
  • Vinorelbine Drug
  • ZW25 (Zanidatamab) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2016
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Last update posted
Nov 26, 2024

2016 – 2024

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35294
USC/Norris Cancer Center Los Angeles California 90033
Hoag Family Cancer Institute Newport Beach California 92663
University of Colorado Cancer Center Aurora Colorado 80045
Rush University Medical Center Chicago Illinois 60612
Sarah Cannon - Tennessee Oncology Nashville Tennessee 37203
MD Anderson Cancer Center Houston Texas 77030
South Texas Accelerated Research Therapeutics (START) San Antonio Texas 78229
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02892123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 26, 2024 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02892123 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →